Skip to content

Alumis Inc. ALMS Additional Paid-In Capital

Additional Paid-In Capital at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$46.37B+0.8%
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$705.2M+51.2%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
$2.35B+1.6%
Vera Therapeutics logo
Vera TherapeuticsVERA
$1.38B+31.9%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
$1.58B+197%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$1.12B+7.8%

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.12B+739%
Enterprise value$3.1B+1,238%
P/S371.9×

Profitability

See full
Operating margin-5,364%
Net margin-2,825.7%
FCF margin-4,487.4%

Returns & leverage

See full
Return on equity-64.6%
Debt / equity0.1×+0.1×
Current ratio7.5×+3.8×

Where this comes from

Reported directly by Alumis Inc. in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.

The official record: Alumis Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alumis Inc.'s additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alumis Inc.'s additional paid-in capital?
Alumis Inc. (ALMS) reported additional paid-in capital of $1.56B in Q1 2026.
How has Alumis Inc.'s additional paid-in capital changed year-over-year?
Alumis Inc.'s additional paid-in capital increased by 68.8% year-over-year, from $925.83M to $1.56B.
What is the long-term trend for Alumis Inc.'s additional paid-in capital?
Over 2 years (2023 to 2025), Alumis Inc.'s additional paid-in capital has grown at a 592.9% compound annual growth rate (CAGR), from $25.06M to $1.2B.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.